News

RINVOQ is expected to be available in the U.S. in late August 2019. The FDA approval of RINVOQ is supported by data from the SELECT program, one of

Inrebic is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). It is a

“We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis

The acquisition provides the combined company with a comprehensive, integrated set of RNA-based solutions to enhance drug development by identifying the right patients for oncology drugs, improving response

The company has also received accelerated approval for Rozlytrek to treat adult and paediatric patients 12 years of age and older with solid tumours, which have a neurotrophic

The late-stage study called PAOLA-1 evaluated Lynparza plus bevacizumab in the first line maintenance setting in comparison to bevacizumab alone in women with advanced ovarian cancer, irrespective of

The IXORA-R trial is the first completed head-to-head (H2H) trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as

The financing was co-led by RTW Investments and Perceptive Advisors (Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund), and joined by additional new investors, including Osage University

The approval has been granted for the use of ibrutinib in combination with obinutuzumab in adult patients with previously untreated chronic lymphocytic leukaemia (CLL), as well as the